Clinical Trial Update: Medical Access Program for Patritumab Deruxtecan

View source ↗

Summary

The Medical Access Program for patritumab deruxtecan in EGFR-mutated non-small cell lung cancer is no longer available.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Patritumab Deruxtecan (patritumab deruxtecan)

Snippet

Sponsor: Daiichi Sankyo | Conditions: Epidermal Growth Factor Receptor (EGFR)-Mutated Non Small Cell Lung Cancer | Status: NO_LONGER_AVAILABLE